To establish a celiac disease screening pilot program
Summary
This bill establishes a 3-year pilot program within the Department of Public Health to evaluate whether celiac disease screening should be added when health care providers conduct cholesterol and lipid screenings for 12-year-olds in Massachusetts. The program is framed as an emergency law so it can take effect immediately, and it is intended to test the feasibility, accuracy, and outcomes of screening children at that age.
The bill directs the department to support participating providers, collect screening-related data, provide educational materials for families, and work with insurers and patient advocacy groups. It also requires an annual report to the Legislature on the program’s effectiveness, cost savings, financial sustainability, collected data, and any recommendations for expanding celiac screening statewide.
Impact
The bill would not immediately mandate universal celiac screening statewide, but it would create a state-run pilot that could influence future public health policy and clinical screening standards. It authorizes the Department of Public Health to coordinate with health care providers, insurers, and advocacy organizations, and it allows participating providers to collect and report data at no additional cost. Subject to appropriation, the department would also be responsible for funding implementation and evaluation, and the annual reports could inform later legislation or regulatory action expanding screening beyond the pilot population.
Sentiment
The bill’s overall tone is supportive and preventive, emphasizing early detection, reduced long-term health consequences, and family support for children diagnosed with celiac disease. Because there are no recorded committee transcripts or votes in the provided material, there is no documented opposition or formal debate to indicate broader legislative sentiment. The bill text itself suggests a public health-oriented consensus approach focused on evaluation before any statewide expansion.
Contention
The main potential points of contention are likely to be cost, administrative burden, and the clinical value of adding celiac screening to existing cholesterol and lipid screenings for 12-year-olds. The bill explicitly requires analysis of cost savings and financial sustainability and makes implementation subject to appropriation, indicating that funding and resource allocation may be central concerns. Another possible issue is whether screening should be targeted to a specific age group and whether the evidence from the pilot will be sufficient to justify broader adoption.